Metabolic Syndrome in Lung Disease Patient and Its Impact on Other Organs
Pan-African Journal of Health and Psychological Sciences · 04.04.2026 · 2 (2)
DOI: 10.64261/v06s3029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pan-African Journal of Health and Psychological Sciences, online erschienen am 04.04.2026. Verfasst von Firoz Khan und 5 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Insulin resistance, obesity, dyslipidemia, and hypertension are among the conditions that make up metabolic syndrome, a complex disorder that significantly affects patients with lung conditions like asthma, interstitial lung disease, and chronic obstructive pulmonary disease. These conditions also increase the risk of cardiovascular disease and type-2 diabetes mellitus. The pathophysiology of metabolic syndrome is examined in this review, with particular attention paid to the roles played by insulin resistance, chronic inflammation, the intricate interactions between lung illnesses and metabolic syndrome, systemic inflammation, oxidative stress, and immune system activation. Chronic renal disease, nonalcoholic fatty liver disease, cardiovascular disease, and cognitive decline are among the multi-organ consequences that are exacerbated by these conditions, which also contribute to pulmonary symptoms. Clinical ramifications are examined, emphasizing the elevated risks of frailty, cognitive decline, and cardiovascular illness, especially in older persons and particular gender groupings. To emphasize the significance of early intervention, management methods are examined, including pharmaceutical treatments, lifestyle modifications, and innovative therapeutic approaches like telmisartan and sacubitril/valsartan. This study also emphasizes the value of a multidisciplinary approach to treatment, combining pharmaceutical treatments (statins, GLP-1 agonists), lifestyle changes, and new treatments (endolytic, gut-lung axis regulation). In order to improve patient outcomes and lower morbidity and mortality, the report ends with a call for targeted medicines to address the underlying processes of Metabolic Syndrome in high-risk populations. These efforts target pulmonary components.
Zitieren
APA
Khan, F., Malik, S. H., Singh, T., Ashraf, R., Hussain, I., & Mahajan, D. (2026). Metabolic Syndrome in Lung Disease Patient and Its Impact on Other Organs. Pan-African Journal of Health and Psychological Sciences, 2(2). https://doi.org/10.64261/v06s3029
Vancouver
Khan F, Malik SH, Singh T, Ashraf R, Hussain I, Mahajan D. Metabolic Syndrome in Lung Disease Patient and Its Impact on Other Organs. Pan-African Journal of Health and Psychological Sciences. 2026;2(2). doi:10.64261/v06s3029
BibTeX
@article{Khan2026,
author = {Khan, Firoz and Malik, Shafkat Hussain and Singh, Taranvirinderdeep and Ashraf, Ruhit and Hussain, Imtiyaz and Mahajan, Dakush},
title = {Metabolic Syndrome in Lung Disease Patient and Its Impact on Other Organs},
journal = {Pan-African Journal of Health and Psychological Sciences},
year = {2026},
volume = {2},
number = {2},
doi = {10.64261/v06s3029}
}
EUVIMED